Over the years, Ellex has evolved from a small scientific laser company to a global leader in ophthalmic laser technology. Our steady expansion includes local sales and service support offices in North America, Japan, Europe and Australia and a network of distribution partners in more than 100 countries.

ASX Releases

Additional Financial Information on Segment Results for the half year ended 31 December 2017

9 March 2018

Adelaide, Australia 9 March 2018 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today provided detailed information on the profit and loss for each business segment. This provides investors with greater understanding of the investment being made in Ellex iTrack™ sales and marketing and the impact on the financial results. This information is attached and can be read in conjunction with the consolidated financial results for the half year ended 31 December 2017 issued on 27 February 2018. View the profit and loss statement here   ABOUT ELLEX Ellex designs, develops, manufactures and sells innovative products that help eye surgeons around the world to effectively and efficiently treat eye disease. Ellex is a world leader in this field. Headquartered in Adelaide, Australia, Ellex has ophthalmic lasers and devices that treat glaucoma, retinal disease primarily caused by diabetes, secondary cataract and vitre


Ellex at American Glaucoma Society Meeting, New York City

7 March 2018

Adelaide, Australia 7 March 2018 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced that the company has successfully showcased its glaucoma products at the American Glaucoma Society (AGS) 2018 Annual Meeting in New York City, 1-3 March 2018. The AGS Annual Meeting is the pre-eminent event for glaucoma specialists in the USA, comprising both a scientific program and a tradeshow exhibition. Approximately 1,100 physicians attended the 2018 meeting, an increase of 30% on the prior year, providing a strong platform for Ellex to continue its marketing drive targeting the global glaucoma market with its innovative products. Highlights of the AGS 2018 Meeting included: • Confirmation that the minimally invasive glaucoma surgery (MIGS) market segment is a viable current and long term future alternative to pharmaceuticals for managing glaucoma with a strong emphasis on the role of MIGS discussed in the sci


Release of Financial Results for Half-Year ended 31 December 2017

27 February 2018

Highlights:  • Record sales revenue of A$38 million for the half achieved as Ellex’s glaucoma market penetration strategy gains traction  • Revenue and earnings in line with previous trading update  • Cash balance of A$25 million – Ellex well capitalised to grow top line revenue through glaucoma focus  • 65% uplift in USA sales of lead product Ellex iTrackTM and 9% lift in Core Laser and Ultrasound business sales resulted in 12% growth in Group sales compared with the prior corresponding period  • Revenue expected to continue to increase in the second half  Adelaide, Australia 27 February 2018 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today released its audited financial results for the half-year ended 31 December 2017. Performance and Strategy During the period, Ellex continued to invest capital in the glaucoma market penetration strategy, primarily for its consumable Ellex iTrack™ catheter. Ellex iTrac


Annual Report 2016

View Share Price

Note: Prices are delayed by at least 20 minutes and are sourced from the Australian Stock Exchange. Retrieving price information indicates your acceptance of the conditions.

Corporate Governance

Share Trading Policy